All products are handled with strict quality standards to ensure consistent research-grade excellence.
Our checkout is SSL encrypted and completely secure.
Our products are verified by independent third party laboratories to meet quality standards.
All product batches and lots are assigned unique identifiers and tied to publicly posted lab reports.
We are committed to helping our customers. If you have any questions or concerns, please reach out through our Contact Us page.
Price range: $54.99 through $175.99
| Quantity | Discount | Price |
|---|---|---|
| 5 - 10 | 5% | $167.19 |
| 11 - 20 | 10% | $158.39 |
| 21+ | 15% | $149.59 |
Every batch of our research chemicals and peptides undergoes third-party testing.
*Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes. Kindly review our Terms & Conditions before making a purchase.
Always quality-tested, verified with third party COA’s
At every step, we prioritize quality by conducting rigorous third-party testing on all our products. These tests focus on five key characteristics- identity, purity, sterility, and endotoxin levels, and heavy metal content-ensuring that each product meets the highest standards of quality with independent third-party Certificates of Analysis (COAS) to verify our commitment to excellence.
*Disclaimer: This product is intended solely for laboratory research purposes. It is not suitable for consumption by humans, nor for medical, veterinary, or household purposes.Kindly review our Terms & Conditions before making a purchase.
Shop GLP 3 Peptide in 10 mg and 20 mg vials. Eternal Peptides ensures rigorous testing, full traceability, and certified 99%+ purity backed by third-party COAs. Order GLP-3 (R) today to enjoy fast, secure U.S. shipping and responsive customer support.
This molecule is a synthetic triple-agonist research peptide engineered to interact with three key metabolic receptor families commonly studied in energy-balance and nutrient-signaling research. By simultaneously engaging multiple G-protein–coupled receptor pathways, this peptide allows investigators to model highly integrated metabolic responses that cannot be reproduced with single or dual-agonist compounds.
Eternal Peptides takes customer confidence and privacy with the utmost seriousness. We’re one of very few peptide shops that accept Cashapp, Zelle, and Bitcoin payments. Shipping is secure and discreet, with each order carefully packed to ensure the integrity of the vials and their contents.
We do our best to process orders within 24 hours and ship via USPS Priority (2–4 business days) or 1–2 day Express. We also offer free Priority shipping on orders over $200.
In keeping with international standards, Eternal Peptides maintains rigorous quality and purity standards, and every peptide batch is independently tested for purity, sterility, endotoxins and heavy metals – we don’t cut corners. We ensure complete traceability and batch-to-batch consistency for complete research confidence.
Enjoy responsive support & customer care: Contact us by email or message, and our team typically replies within 12 hours (max 24h).
Plus, we have amazing bundle savings and discounts: Save more when you build larger stacks or subscribe to our newsletter and let us be your long-term research partner.
Triple-agonist peptides are designed to activate three distinct yet interconnected metabolic hormone receptors: GLP-1R, GIPR, and GCGR. In non-clinical and early clinical research, this coordinated receptor engagement has provided a unique window into how multiple metabolic pathways interact when stimulated simultaneously.
Studies show that triple-agonists influence metabolic circuits responsible for nutrient sensing, fuel selection, and substrate utilization[1]. By engaging incretin receptors alongside the glucagon receptor, these peptides help researchers observe how the body shifts between glucose and lipid metabolism, how nutrients are partitioned across tissues, and how hormonal signals regulate anabolic vs. catabolic states.
GCGR activation adds an important energetic dimension. In research models, triple-agonists have been associated with increased thermogenesis, enhanced fat oxidation, and shifts in resting energy expenditure[2]. These findings allow investigators to examine how incretin signaling and glucagon pathways interact to regulate whole-body energy balance.
Because the three receptors jointly regulate insulin secretion, glucagon suppression, hepatic glucose output, and appetite cues, triple-agonists offer a powerful tool for studying endocrine feedback systems. Researchers can observe how hormonal cross-talk contributes to glucose control, insulin sensitivity, and compensatory mechanisms triggered by prolonged receptor stimulation[3].
Triple-agonists provide an experimental framework for exploring multi-pathway receptor activation, enabling mechanistic studies not possible with mono- or dual-agonist compounds[4].
This includes mapping receptor-specific contributions, evaluating synergistic effects, and analyzing downstream signaling networks across metabolic tissues such as liver, adipose, muscle, and the central nervous system.
The combined receptor-activity profile of triple-agonists makes them particularly valuable for:
By enabling simultaneous modulation of multiple hormonal axes, triple-agonists help researchers interrogate complex physiological interactions that cannot be replicated with single-pathway agents.
| Property | Details |
| Type | Synthetic triple-agonist research peptide |
| Form | Lyophilized powder |
| Purity | ≥ 99% (third-party verified) |
| Sequence | Provided on COA |
| Molar Mass | Provided on COA |
| Synonyms | Multi-receptor agonist peptide / Triple-pathway agonist peptide |
| Storage | Store at -4 °F (–20 °C) dry, protected from light |
| Reconstitution | Use bacteriostatic water or other sterile research-grade solvent as appropriate |
Eternal Peptides is committed to providing clear, traceable documentation to support peptide quality and purity. Every vial is accompanied by a third-party COA detailing:
COAs are available on our Lab Tests page or upon request.
Eternal Peptides sells Triple-G agonists exclusively for research applications. This product is not for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications.
Buyers agree to adhere to all local, state, and federal regulations upon purchase of this product.
GLP-3–type triple-agonist peptides are currently studied in metabolic research models investigating energy balance, nutrient signaling, and endocrine feedback mechanisms. In experimental systems, researchers examine how simultaneous activation of GLP-1R, GIPR, and GCGR influences metabolic signaling pathways related to glucose regulation, lipid metabolism, and energy expenditure.
Despite promising observations in pre-clinical studies, please note that these compounds are research peptides and are not approved for medical use.
GLP-1 refers to a naturally occurring incretin hormone that primarily activates the GLP-1 receptor and is involved in insulin secretion and glucose signaling. GLP-3–type peptides, by contrast, are synthetic triple-agonist research compounds designed to interact with three receptor systems simultaneously: GLP-1R, GIPR, and GCGR. This multi-receptor activation allows researchers to study integrated metabolic signaling across multiple endocrine pathways.
No. GLP-3 triple-agonist peptides are investigational research compounds and are not approved by the U.S. Food and Drug Administration for medical, diagnostic, or therapeutic use. These peptides are supplied strictly for laboratory research purposes, where they are studied in experimental models investigating metabolic signaling and receptor pathway interactions.
The term “GLP R3” is sometimes used informally in research discussions to reference peptides designed to interact with three glucagon-like peptide–related receptor pathways. In the context of triple-agonist research peptides, this typically refers to compounds engineered to activate GLP-1 receptors, GIP receptors, and glucagon receptors simultaneously in experimental metabolic signaling studies.
Leading pharmaceutical company Eli Lilly has developed an approved medication that operates through a similar triple-receptor mechanism involving GLP-1, GIP, and glucagon signaling pathways. However, the GLP-R3 research peptide referenced here is an experimental compound intended solely for laboratory investigation. It is not the same as the approved pharmaceutical product and should not be considered interchangeable.
A triple-agonist peptide is a synthetic research compound engineered to activate three metabolic hormone receptors simultaneously. In the case of GLP-3–type peptides, the primary targets are GLP-1 receptors (GLP-1R), glucose-dependent insulinotropic polypeptide receptors (GIPR), and glucagon receptors (GCGR). By stimulating multiple G-protein–coupled receptor pathways at once, researchers can study how interconnected metabolic and endocrine signaling systems respond to coordinated receptor activation.
Triple-agonist peptides are frequently studied because they allow researchers to model complex metabolic signaling interactions across multiple hormone pathways. In experimental systems, these peptides are used to investigate nutrient sensing, endocrine feedback mechanisms, energy balance signaling, and cross-talk between metabolic tissues such as liver, adipose tissue, skeletal muscle, and the central nervous system.
Triple-agonist peptides are typically supplied as lyophilized powders to preserve stability during storage and transport. In laboratory environments, researchers commonly prepare experimental solutions by reconstituting the peptide with bacteriostatic water or another sterile research-grade solvent. The solvent is generally introduced slowly along the vial wall, followed by gentle mixing to dissolve the peptide before aliquoting for experimental use.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12304053/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12567493/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9450567/
https://pmc.ncbi.nlm.nih.gov/articles/PMC12560177/
About the Author:
Dr. Sony Sherpa, MBBS, MD
is a board-certified clinician with a background in emergency medicine and clinical practice. She specializes in medical research analysis, ensuring that product information is grounded in evidence-based medicine and strictly adheres to the latest scientific standards in peptide research and recovery.
